EN PL
ORIGINAL PAPER
The effects of synthetic immunostimulator polyoxidonium on methotrexate treatment in rats with adjuvant arthritis
 
More details
Hide details
 
Online publication date: 2011-12-28
 
 
Reumatologia 2011;49(6):411-418
 
KEYWORDS
ABSTRACT
The purpose of this study was to evaluate the effect of polyoxidonium (POX) on prophylactic treatment of adjuvant arthritis (AA) with methotrexate (MTX) in rats. Groups of rats with AA were treated with methotrexate (1 mg/kg/week), polyoxidonium (0.1 mg/kg) or their combination for a period of 28 days from adjuvant application. Body mass, hind paw swelling, arthrogram scores and a level of serum albumin were measured as markers of inflammation and arthritis. Treatment with low doses of methotrexate significantly inhibited the markers of both inflammation and arthritis. Methotrexate and its combination with POX significantly increased body mass of arthritic rats. Polyoxidonium administered alone had no significant effect on the hind paw swelling and arthritic score. In combination with MTX, POX markedly potentiated the beneficial effects of MTX, which resulted in a more significant reduction of hind paw swelling and arthritic scores. The concentration of albumin in the serum of arthritic controls was significantly lower than in healthy controls. Both MTX alone and the combination treatment with MTX + POX significantly inhibited the decrease in serum albumin. Polyoxidonium increased the treatment efficacy of basal treatment of AA with MTX (Tables I–IV). In patients with rheumatoid arthritis this immunomodulator may prevent the secondary infections and restore impaired immunological homeostasis.
REFERENCES (17)
1.
Dyakonova VA, Dambaeva SV, Pinegin BV, Khaitov RM. Study of interaction between the polyoxidonium immunomodulator and the human immune system cells. Int Immunopharmacol 2004; 4: 1615-1623.  .
 
2.
Dambaeva SV, Mazurov DV, Golubeva NM, et al. Effect of polyoxidonium on the phagocitic activity of human peripheral blood leukocytes. Russ J Immunol 2003; 8: 53-60.  .
 
3.
Pinegin BV, Nekrasov AV, Khaitov RM. Immunomodulator polyoxidonium: mechanisms of action and aspects of clinical application. Cytokines and Inflammation 2004; 3: 41-47.  .
 
4.
Petrov RV, Khaitov RM. Vaccines of new generation on the base of synthetic polyions: the history of design, phenomenology and mechanisms of action, implementation to practice. Immunologiya 1998; 5: 4–11 (in Russian).  .
 
5.
Kazeko NI, Zhmurov VA, BorovskiI˘ AA, et al. Polyoxidonium in the treatment of calculous pyelonephritis. Urologiia 2006; 2: 9-62 (in Russian).  .
 
6.
Borisova AM, Laktionova LV, Setdikova NK. Clinical trial of domestic drug polyoxidonium in secondary immunodeficiency. Ter Arkh 1998; 70: 52-57 (in Russian).  .
 
7.
Mikheeva GN, Khaitov RM. Current aspects of diagnosis and treatment of atopic diseases complicated by secondary immuno­deficiency. Ter Arkh 1998; 70: 54-60 (in Russian).  .
 
8.
Zemskov AM, Kiselev AV, Koveshnikov VV. Immune status of patients with exacerbation of chronic suppurative otitis media and its correction. Vestn Otorinolaringol 2010; 5: 38-40 (in Russian).  .
 
9.
Buniatian AA, Inviiaeva EV, Nikoda VV, VinnitskiI˘ LI. Immunocorrectors in the complex treatment of postoperative suppurative-inflammatory complications in surgical patients and monitoring of immunological parameters. Anesteziol Reanimatol 2004; 5: 79-83 (in Russian). .
 
10.
Pylaeva SI, Gordinskaia NA, Vazina IR, Sidorkin VG, Bushuev IuI. The prevention of suppurative-septic complications in severe burns by using immunotropic drug preparations in an experiment. Zh Mikrobiol Epidemiol Immunobiol 2000; 1: 72-75 (in Russian). .
 
11.
West SG. Methotrexate hepatoxicity. Rheum Dis Clin North Am 1997; 23: 83-91. .
 
12.
Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-328. .
 
13.
Welles WL, Silkworth J, Oronsky AL, Kerwar SS, Galivan J. Studies on the effect of low dose methotrexate in adjuvant arthritis. J Rheumatol 1985; 12: 904-906. .
 
14.
Connolly KM, Stecher VJ, Danis E, et al. Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int J Immunopharmacol 1988; 10: 717-728. .
 
15.
ZabrodskiI˘ PF, Kirichuk VF, Iafarova IKh, et al. Reduction of the immune responses and synthesis of cytokines associated with Th1 and Th2 lymphocyte function and their correction by polyoxidonium under conditions of subacute intoxication by organophosphorus compounds. Eksp Klin Farmakol 2009; 72: 33-35 (in Russian). .
 
16.
ZabrodskiI˘ PF, Svistunov AA, Lim VG, et al. Pharmacological correction of Th1 and Th2 lymphocyte activity and cytokine profile in ethanol intoxicated rats. Eksp Klin Farmakol 2010; 73: 19-21 (in Russian). .
 
17.
Morrow J, Nelson JL, Watts R, Isenberg D. Therapeutic manipulation of the immune system. In: Autoimmune Rheumatic Disease, 2nd edition, (eds.). Morrow J, Nelson JL, Watts R, Isenberg D. Oxford University Press, Oxford 1999; 43-56.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top